Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S. Weber(NYU Langone Health), Tal Zaks(Moderna Therapeutics (United States)), Ryan J. Sullivan(Dana-Farber Cancer Institute), Kevin B. Kim(The University of Texas MD Anderson Cancer Center), Praveen Aanur(Moderna Therapeutics (United States)), Michelle Brown(Moderna Therapeutics (United States)), C. Lance Cowey(Texas Oncology), Geoffrey T. Gibney(Georgetown University), Theresa Medina(University of Colorado Cancer Center), Céline Robert-Tissot(Moderna Therapeutics (United States)), Matthew H. Taylor(Providence Portland Medical Center), Andrew L. Pecora(Hackensack University Medical Center), Jennifer Segar(University of Arizona), Peijie Hou(Moderna Therapeutics (United States)), Jason J. Luke(University of Chicago), Sajeve Thomas(Orlando Health), Elizabeth I. Buchbinder(Massachusetts General Hospital), Georgina V. Long(The University of Sydney), Tarek Meniawy(St John of God Subiaco Hospital), Mark B. Faries(Angeles Clinic and Research Institute), George Ansstas(Washington University in St. Louis), Matteo S. Carlino(The University of Sydney), Montaser Shaheen(The University of Texas at San Antonio Health Science Center), Robert Meehan(Moderna Therapeutics (United States)), Igor Feldman(Moderna Therapeutics (United States)), Mo Huang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Manju Morrissey(Moderna Therapeutics (United States)), Victoria Atkinson(Greenslopes Private Hospital), Vasudha Sehgal(Moderna Therapeutics (United States)), Adnan Khattak(Edith Cowan University), Meredith McKean(Sarah Cannon), Jane A Healy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Thuy Tran(Yale Cancer Center)
Cited by 729
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k